The approval of the first-ever pill treating postpartum depression on Friday was hailed as a significant milestone, but it was quickly tempered by questions around how much the drug will cost.
The results of the closely watched 'SELECT' trial, which exceeded analyst expectations, were seen as a major boost for the firm's hopes of moving beyond Wegovy's image as a 'vanity drug.'
Citing understaffing and unacceptable working conditions, pharmacists working at a Tampa veterans hospital have passed a vote of no confidence in the hospital’s pharmacy and executive leadership.
With the lift from pandemic vaccine and drug sales over, Pfizer CEO bets on new drug approvals and deals.
The pandemic showered Pfizer with record sales. Now the end of the crisis is dragging the drugmaker down.
Its Covid-19 vaccine and drug powered Pfizer to more than $100 billion in sales last year, the first drugmaker to break the barrier. Shares soared, as Wall Street hailed the company for its savvy, fast and ultimately lucrative pivot to taking on the virus.
But many people have moved on from the pandemic. Sales from the two products dropped so much, so rapidly they contributed to Pfizer’s overall sales falling sizably in its most recent quarter compared with the period a year earlier. The company dialed back the top end of its expectations for the full-year performance.